Mural Oncology plc (MURA)

Market Cap	54.32M
Revenue (ttm)	n/a
Net Income (ttm)	-153.78M
Shares Out	17.08M
EPS (ttm)	-9.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	201,901
Open	3.300
Previous Close	3.140
Day's Range	3.100 - 3.300
52-Week Range	2.870 - 6.250
Beta	n/a
Analysts	Strong Buy
Price Target	16.00 (+403.15%)
Earnings Date	Nov 13, 2024

About MURA

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 117
• Stock Exchange: NASDAQ
• Ticker Symbol: MURA
• Website: https://www.muraloncology.com

Analyst Forecast

According to 4 analysts, the average rating for MURA stock is "Strong Buy." The 12-month stock price forecast is $16.0, which is an increase of 403.15% from the latest price.

Price Target

$16.0

(403.15% upside)

Analyst Consensus: Strong Buy